Hostname: page-component-84b7d79bbc-dwq4g Total loading time: 0 Render date: 2024-07-28T10:27:17.508Z Has data issue: false hasContentIssue false
  • English
  • Français

Psychological and biological mechanisms of cytokine induced depression

Published online by Cambridge University Press:  11 April 2011

Nilay Hepgul ,
Valeria Mondelli  and
Carmine M. Pariante
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Depression is frequently seen in patients with medical illnesses yet the link between medical illnesses and depression remains unclear. There is increasing data to suggest that the array of depressive symptoms experienced by the medically-ill may involve inflammation. The activation of the immune system and the subsequent release of innate immune products such as cytokines can have important effects on behaviour. The treatment of choice for chronic viral hepatitis C, interferon-alpha IFN-α, acutely induces the production and release of other innate immune cytokines, and has been indicated to cause clinically significant depression in 30% of patients receiving treatment. This in turn can impair quality of life and affect treatment compliance. We and others use IFN-α induced depression as a model to identify alterations in psychological and biological pathways that predispose to depression in the medically-ill, and thus provide an explanatory link between inflammation and the subsequent behavioural changes. In this editorial, we aim to describe the main biological pathways involved in IFN-induced depression and to discuss psychological, clinical and biological factors that have been found to predict those who will develop more severe psychiatric symptoms during treatment with IFN-α. Among these, particular attention would be given to psychological traits, genetic polymorphisms regulating inflammation and serotonergic function, and changes in plasma levels of pro-inflammatory cytokines.

Type
Editorials
Information
Epidemiology and Psychiatric Sciences , Volume 19 , Issue 2 , June 2010 , pp. 98 - 102
Copyright
Copyright © Cambridge University Press 2010

References

Agarwal, K., Cross, T.I. & Gore, C. (2007). Chronic hepatitis C. British Medical Journal 334, 54–55.CrossRefGoogle ScholarPubMed
Asnis, G.M. & De La Garza, (2006). Interferon induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology and treatment approaches. Journal of Clinical Gastroenterology 40, 322–335.CrossRefGoogle ScholarPubMed
Bhagwagar, Z., Hafizi, S. & Cowen, P.J. (2005). Increased salivary cortisol after waking in depression. Psychopharmacology 182, 54–57.CrossRefGoogle ScholarPubMed
Bonaccorso, S., Marino, V., Puzella, A., Pasquini, M., Biondi, M., Artini, M., Almerighi, C., Meltzer, H. & Maes, M. (2002). Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. Journal of Clinical Psychopharmacology 22, 86–90.CrossRefGoogle ScholarPubMed
Bouhuys, A.L., Flentge, F., Oldehinkel, A.J. & van den Berg, M.D. (2004). Potential psychosocial mechanisms linking depression to immune function in elderly subjects. Psychiatry Research 127, 237–245.CrossRefGoogle ScholarPubMed
Bull, S.J., Huezo-Diaz, P., Binder, E.B., Cubells, J.F., Ranjith, G., Maddock, C., Miyazaki, C., Alexander, N., Hotopf, M., Cleare, A.J., Norris, S., Cassidy, E., Aitchison, K.J., Miller, A.H. & Pariante, C.M. (2009). Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferonalpha and ribavirin treatment. Molecular Psychiatry 14, 1095–1104.CrossRefGoogle ScholarPubMed
Capuron, L. & Miller, A.H. (2004). Cytokines and psychopathology: lessons from interferon-alpha. Biological Psychiatry 65, 819–824.CrossRefGoogle Scholar
Capuron, L., Gumnick, J.F., Musselman, D.L., Lawson, D.H., Reemsnyder, A., Nemeroff, C.B. & Miller, A.H. (2002). Neurobehavioural effects on interferon-alpha in cancer patients: phenomology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26, 643–652.CrossRefGoogle Scholar
Capuron, L., Raison, C.L., Musselman, D.L., Lawson, D.H., Nemeroff, C.B. & Miller, A.H. (2003). Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. American Journal of Psychiatry 160, 1342–1345.CrossRefGoogle Scholar
Caspi, A., Sugden, K., Moffitt, T.E., Taylor, A., Craig, I.W., H.L., Harrington, J., McClay, J., Mill, J., Martin, A., Braithwaite & R., Poulton (2003). Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301, 386–389.CrossRefGoogle ScholarPubMed
Danese, A., Moffitt, T.E., Pariante, C.M., Ambler, A., Poulton, R. & Caspi, A. (2008). Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Archives of General Psychiatry 65:409–415.CrossRefGoogle ScholarPubMed
Dantzer, R., O'Conner, J.C., Freund, G.G., Johnson, R.W. & Kelley, K.W. (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience 9, 46–56.CrossRefGoogle ScholarPubMed
Evans, D.L., Charney, D.S., Lewis, L., Golden, R.N., Gorman, J.M., Krishnan, K., Nemeroff, C., Bremner, J., Carney, R. & Coyne, J. (2005). Mood disorders in the medically ill: scientific review and recommendations. Biological Psychiatry 58, 175–189.CrossRefGoogle Scholar
Freeman, M.P., Hibbeln, J.R., Wisner, K.L., Davis, J.M., Mischoulon, D., Peet, M., Keck, P.E. Jr, Marangell, L.B., Richardson, A.J., Lake, J. & Stoll, A.L. (2006). Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. Journal of Clinical Psychiatry 67, 1954–1967.CrossRefGoogle ScholarPubMed
Hunt, C.M., Dominitz, J.A., Philipis-Bute, B., Waters, B., Blasi, U. & Williams, D.M. (1997). Effect of interferon-alpha treatment of chronic hepatitis C on health related quality of life. Digestive Diseases and Sciences 42, 2482–2486.CrossRefGoogle ScholarPubMed
Kozak, W., Soszynski, D., Rudolph, K., Conn, C.A. & Kluger, M.J. (1997). Dietary n-3 fatty acids differentially affect sickness behavior in mice during local and systemic inflammation. American Journal of Physiology 272, 1298–1307.Google ScholarPubMed
Lotrich, F.E., Rabinovitz, M., Gironda, P. & Pollock, B.G. (2007). Depression following pegylated interferon-alpha: characteristics and vulnerability. Journal of Psychosomatic Research 63, 131–135.CrossRefGoogle ScholarPubMed
Miller, A.H. (2009). Mechanisms of cytokine-induced behavioral changes: Psychoneuroimmunology at the translational interface. Brain, Behaviour and Immunity 23, 149–158.CrossRefGoogle ScholarPubMed
Morasco, B.J., Rifai, M.A., Loftis, J.M., Indest, D.W., Moles, J.K. & Hauser, P. (2007). A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. Journal of Affective Disorders 103, 83–90.CrossRefGoogle ScholarPubMed
Musselman, D.L., Miller, A.H., Porter, M.R., Manatunga, A., Gao, F., Penna, S, Pearce, B.D., Landry, J., Glover, S., McDaniel, J.S. & Nemeroff, C.B. (2001). Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. American Journal of Psychiatry 158, 1252–1257.CrossRefGoogle ScholarPubMed
Myint, A.M., O'Mahony, S., Kubera, M., Kim, Y.K., Kenny, C., Kaim-Basta, A., Steinbusch, H.W.M. & Leonard, B.E. (2007). Role of paroxetine in interferon-alpha-induced immune and behavioural changes in male Wistar rats. Journal of Psychopharmacology 21, 841–850.CrossRefGoogle ScholarPubMed
Pariante, C.M. (2004). Glucocorticoid receptor function in vitro in patients with major depression. Stress 7, 209–219.CrossRefGoogle ScholarPubMed
Pariante, C.M. & Lightman, S.L. (2008). The HPA axis in major depression: classical theories and new developments. Trends in Neuroscience 31, 464–468.CrossRefGoogle ScholarPubMed
Pariante, C.M., Orru, M.G., Baita, A., Farci, M.G. & Carpiniello, B. (1999). Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 354, 131–132.CrossRefGoogle ScholarPubMed
Pariante, C.M., Landau, S. & Carpiniello, B. (2002). Interferon alfainduced adverse effects in patients with a psychiatric diagnosis. New England Journal of Medicine 347, 148–149.CrossRefGoogle ScholarPubMed
Raison, C.L., Capuron, L. & Miller, A.H. (2006). Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends in Immunlogy 27, 24–31.CrossRefGoogle ScholarPubMed
Raison, C.L., Woolwine, B.J., Demetrashvili, M.F., Borisov, A.S., Weinreib, R., Staab, J.P., Zajecka, J.M., Bruno, C.J., Henderson, M.A., Reinus, J.F., Evans, D.L., Asnis, G.M. & Miller, A.H. (2007). Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Alimentary Pharmacology and Therapeutics 25, 1163–1174.CrossRefGoogle ScholarPubMed
Raison, C.L., Borisov, A.S., Woolwine, B.J., Massung, B., Vogt, G. & Miller, A.H. (2008). Interferon-??effects on diurnal hypothalamicpituitary-adrenal axis activity: relationship with proinflammatory cytokines and behaviour. Molecular Psychiatry, June 2 [Epub ahead of print].Google Scholar
Raison, C.L., Borisov, A.S., Majer, M., Drake, D.F., Pagnoni, G., Woolwine, B., Vogt, G., Massung, B. & Miller, A. (2009). Activation of central nervous system inflammatory pathways by interferonalpha: relationship to monoamines and depression. Biological Psychiatry 65, 296–303.CrossRefGoogle ScholarPubMed
Su, K.P., Huang, S.Y., Chiu, T.H., Huang, K.C., Huang, C.L., Chang, H.C. & Pariante, C.M. (in press). Phospholipase A2 and cyclo-oxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biological Psychiatry [epub ahead of print].Google Scholar
Weinrieb, R.M., Auriacombe, M., Lynch, K.G., Chang, K.M. & Lewis, J.D. (2003). A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. Journal of Clinical Psychiatry 64, 1502–1510.CrossRefGoogle ScholarPubMed
Wichers, M. & Maes, M. (2002). The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. International Journal of Neuropsychopharmacology 5, 375–388.CrossRefGoogle ScholarPubMed
Wichers, M.C., Koek, G.H., Robaeys, G., Verkerk, R., Scharpé, S. & Maes, M. (2005). IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Molecular Psychiatry 10, 538–544.CrossRefGoogle ScholarPubMed
Wichers, M.C., Kenis, G., Koek, G.H., Robaeys, G., Nicolson, N.A. & Maes, M. (2007). Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. Journal of Psychosomatic Research 62, 207–214.CrossRefGoogle ScholarPubMed
Wise, M.G. & Taylor, S.E. (1990). Anxiety and mood disorders in medically ill patients. Journal of Clinical Psychiatry 51, 27–32.Google ScholarPubMed